Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is to assess the prevalence of Asthma COPD Overlap in subjects with diagnosed asthma and chronic obstructive pulmonary disease (COPD). The subsequent morbidity and mortality of subjects will be followed up for 3 years.
Rationale:
Around 15 to 20% of COPD patients have features of asthma. These patients have more frequent and more severe exacerbations, and higher medical utilization. The Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines have given joint recommendations on the identification, diagnosis and treatment of these patients having Asthma-COPD Overlap (ACO). These are at present expert opinions and further studies are needed to establish the optimal definitions and treatment options. The recommendations proposed by the guidelines have been adapted for use in the Asia area countries. Nonetheless, the application to clinical practice has not been well established and there are no prevalence data available on the COPD with asthma symptom population or asthma with COPD symptoms population based on the recommended features for identification. This is the current data gap in Asia.
Primary objective:
To determine the proportion and clinical characteristics of patients with ACO as defined by the joint GINA and GOLD recommendation amongst diagnosed COPD and asthma patients seen at the out-patient clinics
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No intervention | Other | No intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of prevalence of Asthma COPD overlap among the asthma and COPD subjects. | To determine the proportion and clinical characteristics of patients with ACO as defined by the joint GINA and GOLD recommendation amongst diagnosed COPD and asthma patients seen at the out-patient clinics. (Assessment: % of subjects with ACO among patients with asthma and COPD respectively) | 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patient with treatment that is different from the guidelines recommendation | To evaluate the gap between guideline recommendations and real-world clinical practice in identifying COPD patients with asthma and asthma patients with COPD | 3 years |
| The percentages of patients on various medications (e.g. inhaled steroid, LABA, LAMA) |
Not provided
Inclusion Criteria:
Subjects must fulfil all of the following criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Subjects with asthma or COPD
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Fanny Ko, MD | Chinese University of Hong Kong | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Prince of Wales Hospital | Hong Kong | Hong Kong |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41904521 | Derived | Ko FWS, Chan KKP, Ng TCC, Lo RLP, Ngai JCL, To KW, Yip WH, Ng JKC, Chan C, Lau CHY, Hui DSC. A 3-year prospective study to assess clinical characteristics and risk factors for exacerbations in patients with asthma-COPD overlap based on the GINA guideline compared with patients with asthma and COPD. Respir Res. 2026 Mar 29;27(1):202. doi: 10.1186/s12931-026-03643-0. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| D001249 | Asthma |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood will be stored for future genetic studies. As there is currently no good biomarker or genetic tests that can identify the cause or suggest the diagnosis of Asthma COPD overlap, this study would like to explore into this.
To review the medications given to COPD patients with asthma and asthma patients with COPD compared to guideline recommendations |
| 3 years |
| The pecentages of patients receiving different symptoms control assessments (e.g. use of Asthma control test, use of COPD assessment test) | To review the current practices of symptom control assessment | 3 years |
| Percentages of subjects with morbidity (e.g. congestive heart failure) | To assess the 3 year morbidity of ACO patient compared to COPD and asthma patients. | 3 years |
| Percentages of subjects with mortality | To assess the 3 year mortality of ACO patient compared to COPD and asthma | 3 years |
| Percentages of patients with various Genetic markers | Genetic markers got differentiating ACO patients from patients with COPD or asthma | 3 years |
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001982 | Bronchial Diseases |
| D012130 | Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |